
ABSTRACT Pradofloxacin is approved orally for dogs and cats and parenterally for cattle and pigs in the U.S. The objective was to determine the pharmacokinetics of pradofloxacin in loggerhead turtles ( Caretta caretta ) and whether the plasma concentration is sufficient to treat susceptible bacteria. Pradofloxacin (200 mg/mL, diluted to 20 mg/mL in sterile saline) 10 mg/kg was administered SC and IV to 16 yearling loggerhead turtles with sparse sampling blood collection. Plasma concentrations were measured via high‐pressure liquid chromatography (HPLC). Pharmacokinetic analysis was performed with nonlinear mixed effects modeling. After SC administration, the peak plasma concentration ( C MAX ) was 9.31 μg/mL and the elimination half‐life was 1.2 h, with bioavailability greater than 100%. After IV administration, the elimination half‐life was 1.3 h, systemic clearance was 0.74 L/kg/h, and volume of distribution was 1.36 L/kg. Pradofloxacin was tolerated IV and SC and well absorbed SC. Despite favorable absorption and C MAX values, the clearance was faster, and half‐life shorter, than other fluoroquinolones in turtles and pradofloxacin in mammals. These concentrations may not be sufficient to reach pharmacokinetic‐pharmacodynamic targets (AUC/MIC) for treating gram‐positive and gram‐negative bacteria in the susceptibility category of < 0.25 μg/mL, according to clinical breakpoints approved by the Clinical & Laboratory Standards Institute.
ABSTRACT The pharmacokinetics of detomidine, vatinoxan, and their combination have not been previously characterized in detail in horses. Detomidine (20 μg/kg), vatinoxan (200 μg/kg), or their combination was administered intravenously to six horses according to a Latin square design. Blood was sampled at various times up to 480 min following administration. Plasma concentrations of detomidine, OH‐detomidine, COOH‐detomidine, and vatinoxan were measured using liquid chromatography/tandem mass spectrometry. Compartmental models were fitted to the time‐concentration data using nonlinear mixed‐effect modeling. A 5‐compartment model provided the best fit for detomidine and its metabolites, whereas the disposition of vatinoxan was best described by a 3‐compartment model. The volume of distribution at steady state was 762 mL/kg for detomidine and 1422 mL/kg for vatinoxan. Total metabolic clearance was 21.6 mL/min/kg for detomidine and 7.1 mL/min/kg for vatinoxan. Clearance of detomidine into OH‐detomidine and of OH‐detomidine into COOH‐detomidine was predicted to be 40 and 7% of their respective clearance. Covariates accounting for the effect of vatinoxan on several parameters improved the model, suggesting that administration of vatinoxan affects the disposition of detomidine. Similarly, covariates suggested that administration of detomidine affects the disposition of vatinoxan.
Small ruminants such as goats are susceptible to abomasal ulceration due to adverse reactions to medications, stress, and inappetence. There is limited pharmacokinetic data regarding the use of famotidine for treatment and prevention of abomasal ulceration in goats. The objective of this study is to report the pharmacokinetic parameters after a single subcutaneous administration of famotidine. Famotidine was administered at a 1.2 mg/kg dose to six healthy goats and plasma samples were collected over a 12-h period. The plasma was analyzed using reverse phase high performance liquid chromatography (HPLC) to measure famotidine concentrations. Using commercially available pharmacokinetic software, noncompartmental analysis was used to determine the pharmacokinetic parameters. The maximum plasma concentration was estimated at 735 ng/mL and the Tmax was 0.64 h. The apparent terminal half-life was 1.29 h, and the mean residence time was 1.82 h. The area under the curve was found to be 1046 h*ng/mL. Five of the 6 goats in this study had been utilized for a previous intravenous famotidine investigation, and when comparing the area under the curve to this study, the range of the estimated bioavailability after subcutaneous administration was 21.43%-135%. Future research performing a pharmacodynamic study measuring the pH of the abomasal fluid could be used to determine the efficacy of famotidine on raising pH levels. Compared to other studies with intravenous administration in goats, subcutaneous administration of famotidine may be a more useful way of maintaining concentrations over time.
Atopica (formerly Novartis, now Elanco Animal Health) is the pioneer veterinary-approved modified cyclosporine authorized by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Despite the availability of several veterinary-specific generics, human generics are frequently substituted extra-label in clinical practice. However, therapeutic equivalence in humans does not guarantee equal bioavailability in dogs, whether comparing these products to one another or to Atopica. As a Biopharmaceutics Classification System Class II compound, cyclosporine's oral absorption is primarily determined by its dissolution rate. This study compared the in vivo dissolution profiles of three human cyclosporine products including Neoral (Novartis), TEVA (TEVA Pharmaceuticals), and Apotex (Apotex Inc) with Atopica using a Distek 2100 A system (USP Apparatus 2, 50 rpm, 500 mL deionized water, 37 degrees C). Primary outcomes included visual capsule rupture time and cyclosporine concentration at 7.5, 15, and 30 min, quantified by high-performance liquid chromatography. Neoral exhibited a shorter mean capsule rupture time compared to Atopica, while TEVA and Apotex showed no difference. At the 30-min mark, no significant differences in concentrations were observed among the products. While these in vitro results suggest comparable dissolution at a critical absorption 30-min time point, the shorter capsule rupture time of Neoral highlights formulation-specific differences. Comprehensive in vivo pharmacokinetic studies are warranted to determine if these human generics are truly interchangeable with Atopica or one another in dogs.
ABSTRACT Monoclonal antibodies (mAbs) represent a rapidly expanding pharmaceutical class in veterinary medicine, with several products now authorized for use in dogs and cats. Limited published articles and veterinarian exposure to the principles of drug development present challenges in interpreting published safety evaluations that inform product labeling and clinical use. This review describes the principles, methods, strengths, limitations, and interpretation of preclinical target animal safety (TAS) studies for veterinary mAbs and is intended to equip veterinarians and researchers with the knowledge to critically evaluate published TAS data and understand how preclinical safety evidence translates to product labeling. TAS studies are conducted in healthy, purpose‐bred animals of the target species using a margin of safety (MOS) approach with supratherapeutic dosing to screen for product risks. The regulatory and scientific framework is based on internationally harmonized guidance for safety evaluation of small molecule therapeutics in veterinary medicine and more than four decades of experience with mAb therapeutics in human medicine. The high target specificity of the mAb drug class enables a hypothesis‐driven evaluation strategy, combining standard endpoints with target‐informed specialized assessments. Terminal gross and histopathological endpoints provide safety data that clinical studies cannot generate, identifying potential adverse effects down to the cellular level. Unique to veterinary medicine, these data are generated directly in the target species. Data interpretation follows a weight‐of‐evidence approach in which findings are presumed treatment‐related until demonstrated otherwise, integrating dose–response relationships, biological plausibility, and both study and historical control data. TAS studies complement the broader safety evaluation continuum, including clinical field studies, pharmacovigilance, and independent research.